The pursuit of eternal youth through biohacking reveals a future where beauty merges with surveillance, as DNA extraction technology becomes a tool for data collection. This raises profound ethical questions about body ownership and who will be left behind in the race for human enhancement.

The air in the Austin hotel lobby crackled with an energy that felt more like a sci-fi convention than a gathering of skincare enthusiasts.
Yet, here they were, the first adopters of body technology, the pilot subjects of our speculative futures, congregating at BDYHAX.
Cyborgs compared their latest prosthetics with the casual ease of discussing new handbags, their bionic limbs humming as they charged alongside iPhones.
An interactive sound installation thrummed in the corner, a chaotic symphony of the room’s manic pulse.
This wasn’t just about tomorrow’s gadgets; it was about reshaping the very essence of humanity, and the implications, it turns out, are far more profound, and perhaps unsettling, than a simple desire for clearer skin.
The most striking revelation from this deep dive into the transhumanist movement isn’t just the quest for immortality or enhanced abilities, but the unexpected bedfellows these aspirations have created.
Who would have thought that the quest for eternal youth would lead beauty brands to partner with the very agencies tasked with national security?
Yet, the CIA’s venture capital arm has indeed provided funding for Skincential Sciences, a company behind the consumer brand Clearista, which promises “skin resurfacing” for a younger look.
The true marvel, or perhaps menace, lies in its patented DNA extraction technology.
This isn’t just about vanity; it’s about data.
The technology painlessly removes a thin layer of skin, revealing unique biomarkers that, as Skincential Sciences CEO Russ Lebovitz explained to Fast Company, can reflect “where you’ve been, what you’ve done, who you are.”
Exfoliation, it seems, has become a potential tool for surveillance, turning our pursuit of a flawless complexion into an unwitting contribution to a vast, personal data archive.
This blurring of lines between cosmetics and covert operations is just one facet of a burgeoning industry that the beauty world now terms “cosmeceuticals.”
It’s a playground of ingredients and technologies that serve dual purposes, often straddling the medical and even the militant.
Elite universities, those bastions of academic purity, are deeply embedded in this landscape.
Shiseido, a global beauty giant, bankrolls Massachusetts’ Cutaneous Biology Research Center, where MIT and Harvard researchers delve into dermatology, holding annual pitch events for students to contribute to the company’s skincare portfolio.
The talent pipeline for this future-forward industry often starts young, with many BDYHAX attendees having met at Boston’s International Genetically Engineered Machine (iGEM) Competition, a fertile ground for future company founders.
Among these pioneers is Edgar Andrés Ochoa Cruz, the self-proclaimed first biohacker in South America.
A judge at iGEM and founder of OneSkin, Cruz’s mission is singular: to solve aging itself.
Biohacking, in his vision, moves beyond mere augmentation to the modification of chromosomes and genetic composition.
If our bodies are a unique sequence of AGCT, biohacking is the revision process, a genetic word processor aiming to rewrite our capacities and health conditions.
Cruz isn’t alone in this ambitious pursuit; he’s in a race with titans.
Peter Thiel, Jeff Bezos, and Elon Musk have poured vast sums into transhumanist ventures.
Google’s secretive Calico focuses on the biology of aging, while Bezos and Thiel back Unity Biotechnology, aiming to reverse age-associated diseases.
The promise of eternal youth, it seems, is a luxury reserved for those who can afford to bankroll its creation.
For established beauty companies, these conferences are scouting grounds.
L’Oréal, with its Dermatological Beauty Division, invests over 1.2 billion euros annually in research, consistently hosting global summits to showcase its technological prowess.
Their partnership with Poietis, a health tech company, is particularly telling.
Poietis employs 3D laser-assisted printers and robotics to print human hair follicles and skin.
This isn’t just a fascinating scientific endeavor; it’s a strategic move to revolutionize product testing.
Printing viable skin in two weeks, hair follicles in three, promises to drastically accelerate the development cycle, potentially rendering animal testing obsolete and, perhaps more disturbingly, eliminating the need for human test subjects who currently earn low wages for product trials.
It’s a capitalist’s dream, a streamlined production cycle that aligns perfectly with the cyborg future.
Cruz, a freight train of ambition, sees bioprinting as a direct path to faster anti-aging discoveries, allowing him to bypass regulatory hurdles and, if successful, patent his molecules to become immensely wealthy.
He embodies the complex blend of opportunist and idealist, driven by a profound belief in building the future he feels he belongs in.
“When you feel that you should have been born in the future,” he stated, “the only option is to build the future, so you can finally get to where you belong.”
But as the dazzling promises of biotech unfold, a critical question emerges: Who truly owns the body, and what are we willing to owe in return for these advancements?
This was powerfully articulated by Meow-Ludo Disco Gamma Meow-Meow, a cyborg attendee who faced legal battles for implanting his transportation card chip into his hand.
His defiant question, “If you don’t own your body and what’s inside it, then what the hell do you own?” cuts to the heart of the matter.
Tech solutionism, the seductive idea that technology can solve all social, cultural, and structural problems, often fails to grant real agency to those who suffer most.
While the transhumanist movement dreams of extending life and enhancing beauty, it often overlooks, or actively marginalizes, those who are considered “broken” or “too stupid to participate.”
I think of the invisible and visibly disabled, like my father, or queer artists fetishized and reviled for their identities.
I think of the femmes, the depressed, the tired, juggling multiple app-based jobs just to keep a roof overhead, accumulating debt in service of Silicon Valley empires.
These are the people who cannot afford a $15,000 titanium leg, a $200 insulin shot, or even a $40 manicure.
These are the people who will be left behind in fantasies of future health, wealth, and beauty.
These are the people who do not get excited by the idea of genetic editing, because it might mean their families, or even themselves, could be edited out of who they are.
They make up everyone I know and love.
The final panel at BDYHAX starkly laid out the core philosophical dilemma.
On a whiteboard, a frantic scrawl emerged: “With enough technology we can make people equal,” pitted against “We can create a society where we treat each other equally without it.”
I rewrote it in my journal, simplifying it to its essence: “Everyone is beautiful in an equal and good society,” versus “We can create a society where beauty doesn’t factor into how we treat each other after all.”
As we hurtle towards a future where beauty is engineered and biology is data, the real challenge isn’t just about what we can build, but what kind of society we choose to inhabit, and who, ultimately, gets to belong.